The Urology Group
Press / Blog /
November 5, 2013

New Weapon, New Hope for Prostate Cancer Patients

By: Gary Kirsh

In our continuing efforts to provide the best possible treatments for our patients, The Urology Group is proud to announce the CyberKnife stereotactic body radiation therapy (SBRT) system will now be part of our prostate cancer treatment offering. This breakthrough technology for prostate cancer patients delivers high doses of radiation with extreme accuracy and requires fewer sessions than traditional treatments.

We are proud to be the only CyberKnife SBRT provider in the nation exclusively focused on prostate cancer.

Despite the name, CyberKnife SBRT is a non-invasive treatment option that involves no cutting. One of the major advantages is the precise delivery of radiation that bombards cancerous cells while minimizing exposure to healthy tissues.

In addition, patients appreciate that CyberKnife SBRT treatments can be completed without anesthesia or the use of a urinary catheter, and are performed as brief outpatient procedures.

A cancer diagnosis can be overwhelming, with many immediate questions and concerns—and the stress of evaluating treatment options can further complicate the issue. However, knowing you have local access to breakthrough technology can give you comfort and confidence in your treatment journey. And that’s what we strive for at the Urology Group.

Here’s more information about CyberKnife SBRT.

Get the latest news about The Urology Group:

Patient Help Center


  • The Urology Group named a Center of Excellence by NAFC
    February 13, 2019
    The Urology Group was recently designated a Center of Excellence by the National Association for Continence. The COE designation is based on evidence of training, clinical experience, resources and patient satisfaction statistics that meet established standards. These rigorous standards ensure that each center that is designated a COE is truly exceptional at providing care for patients with pelvic floor dysfunction and incontinence. MORE...